OMER News and Press, Omeros Corporation From 05/24/23

2023-05-24 13:57:04 ET The Russell 3000 index will have a new look on June 26, after the market opens, when 286 securities will be added and 179 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added an...

2023-05-16 18:55:18 ET Summary HSCT-TMA BLA Resubmission: Omeros plans to resubmit a BLA for narsoplimab, potentially gaining approval by Q2 2024. IgAN Trial Progress: Top-line results for the phase 3 ARTEMIS trial on narsoplimab for IgAN are expected in Q3 2023. Solid Financi...

2023-05-09 22:54:06 ET Omeros Corporation (OMER) Q1 2023 Results Conference Call May 09, 2023 04:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman and CEO Mike Jacobsen - Chief Accounting Officer Nadia Dac - Chief ...

2023-05-09 16:23:57 ET Omeros press release ( NASDAQ: OMER ): Q1 GAAP EPS of -$0.63 misses by $0.09 . At March 31, 2023, we had $371.4 million of cash, cash equivalents and short-term investments available. In addition, we had $10.0 million of accounts receivable. ...

– Conference Call Today at 4:30 p.m. ET – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immuno...

2023-05-08 17:35:59 ET Omeros ( NASDAQ: OMER ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, after market close. The consensus EPS Estimate is -$0.57 Over the last 1 year, OMER has beaten EPS estimates 75% of the time and has beaten revenue esti...

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Ti...

2023-04-25 10:15:15 ET Shares of Omeros Corporation ( NASDAQ: OMER ) spiked in early trading Tuesday after announcing Phase 1 results for OMS906, its candidate for patients with rare hematological disease paroxysmal nocturnal hemoglobinuria (PNH). Citing an interim analysis fr...

At lowest planned subcutaneous dose, Omeros’ MASP-3 inhibitor OMS906 showed clinically and statistically significant improvements in hemoglobin and LDH, which were seen early and maintained throughout the observation period Following 2 doses of OMS906, all patients achieved an in...

2023-04-18 08:45:06 ET Palm Beach, FL – April 18, 2023 – FinancialNewsMedia.com News Commentary – Alcohol consumption and drug abuse have become public health concerns worldwide. Governments are working on ways to detect any symptoms of alcohol consumpt...